Mortality of bullous pemphigoid in Singapore: Risk factors and causes of death in 359 patients seen at the National Skin Centre

British Journal of Dermatology

Volumn 170, Issue 6, 2014, Pages 1319-1326

  Cai, S C S ^a   Allen, J C ^a   Lim, Y L ^b   Chua, S H ^b   Tan, S H ^b   Tang, M B Y ^b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL SKIN CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DAPSONE; DOXYCYCLINE; NICOTINAMIDE; PREDNISOLONE;

ADULT; AGED; ARTICLE; BULLOUS PEMPHIGOID; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CHRONIC LUNG DISEASE; CLINICAL STUDY; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DEMENTIA; DIABETES MELLITUS; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PARKINSON DISEASE; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; PYELONEPHRITIS; RETROSPECTIVE STUDY; RISK FACTOR; SEPTICEMIA; SINGAPORE; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMIC THERAPY; THYROID DISEASE; URINARY TRACT INFECTION; AGE DISTRIBUTION; EPIDEMIOLOGY; MIDDLE AGED; ONSET AGE; SEX RATIO; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGE OF ONSET; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; SEX DISTRIBUTION; SINGAPORE;

EID: 84903279168     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12806     Document Type: Article

References (41)

1. Wong SN, Chua SH,. Spectrum of subepidermal immunobullous disorders seen at the National Skin Centre, Singapore: a 2-year review. Br J Dermatol 2002; 147: 476-80.
2. Langan SM, Smeeth L, Hubbard R, et al,. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the U.K.: population based cohort study. BMJ 2008; 337: a180.
3. Cortés B, Marazza G, Naldi L, et al,. Mortality of bullous pemphi-goid in Switzerland: a prospective study. Br J Dermatol 2011; 165: 368-74.
4. Joly P, Baricault S, Sparsa A, et al,. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132: 1998-2004.
5. Gudi VS, White MI, Cruickshank N, et al,. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol 2005; 153: 424-7.
6. Garcia-Doval I, Taboada AC, Prado MJC,. Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. J Invest Dermatol 2005; 124: 666-7.
7. Doffoel-Hantz V, Sparsa A, Marin B, et al,. [One year follow-up of patients with bullous pemphigoid]. Ann Dermatol Venereol 2009; 136: 407-11 (in French).
8. Joly P, Benichou J, Lok C, et al,. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141: 691-8.
9. Rzany B, Partscht K, Jung M, et al,. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids and old age. Arch Dermatol 2002; 138: 903-8.
10. Parker SR, Dyson S, Brisman S, et al,. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008; 59: 582-8.
11. Colbert RL, Allen DM, Eastwood D, Fairley JA,. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004; 122: 1091-5.
12. Li J, Zuo YG, Zheng HY,. Mortality of bullous pemphigoid in China. JAMA Dermatol 2013; 149: 106-7.
13. Venning VA, Wojnarowska F,. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992; 26: 585.
14. Bernard P, Enginer V, Venot J, et al,. [Survival prognosis in pemphigoid. A cohort analysis of 78 patients]. Ann Dermatol Venereol 1995; 122: 751-7 (in French).
15. Bernard P, Bedane C, Bonnetblanc JM,. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol 1997; 136: 694-8.
16. Roujeau JC, Lok C, Bastuji-Garin S, et al,. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134: 465-9.
17. Savin JA,. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol 1979; 101: 521-34.
18. Department of Statistics Singapore. Yearbook of Statistics Singapore 2011. Singapore: Ministry of Trade and Industry, 2011.
19. Langan SM, Hubbard R, Fleming K, West J,. A population-based study of acute medical conditions associated with bullous pemphigoid. Br J Dermatol 2009; 161: 1149-52.
20. Bastuji-Garin S, Joly P, Picard-Dahan C, et al,. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 1996; 132: 272-6.
21. Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K,. The associations between bullous pemphigoid and drug use: a U.K. case-control study. JAMA Dermatol 2013; 149: 58-62.
22. Bastuji-Garin S, Joly P, Lemordant P, et al,. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011; 131: 637-43.
23. Cordel N, Chosidow O, Hellot MF, et al,. Neurological disorders in patients with bullous pemphigoid. Dermatology 2007; 215: 187-91.
24. Taghipour K, Chi CC, Vincent A, et al,. The association of bullous pemphigoid with cerebrovascular disease and dementia. Arch Dermatol 2010; 146: 1251-4.
25. Langan SM, Groves RW, West J,. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011; 131: 631-6.
26. Chen YJ, Wu CY, Lin MW, et al,. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 2011; 165: 593-9.
27. Brown A, Bernier G, Mathieu M, et al,. The mouse dystonia musculorum gene is a neural isoform of bullous pemphigoid antigen 1. Nat Genet 1995; 10: 301-6.
28. Seppänen A, Suuronen T, Hofmann SC, et al,. Distribution of collagen XVII in the human brain. Brain Res 2007; 1158: 50-6.
29. Li L, Chen J, Wang B, et al,. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160: 1343-5.
30. Desai BS, Monahan AJ, Carvey PM, Hendey B,. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant 2007; 16: 285-99.
31. Orr CF, Rowe DB, Halliday GM,. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002; 68: 325-40.
32. Whitton PS,. Inflammation as causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007; 150: 963-76.
33. Liu Z, Guidice GJ, Swartz SJ, et al,. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995; 95: 1539-44.
34. McGeer PL, McGeer EG,. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004; 10 (Suppl. 1): S3-7.
35. Bonifati DM, Kishore U,. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 2006; 44: 999-1010.
36. Loeffler DA, Camp DM, Conant SB,. Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study. J Neuroinflammation 2006; 3: 29.
37. Young BA, Maynard C, Boyko EJ,. Racial differences in diabetic nephropathy, cardiovascular disease and mortality in a national population of veterans. Diabetes Care 2003; 26: 2392-9.
38. Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G,. A systematic review of treatments for bullous pemphigoid. Arch Dermatol 2002; 138: 385-9.
39. Joly P, Roujeau JC, Benichou J, et al,. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-7.
40. Fivenson DP, Breneman DL, Rosen GB, et al,. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753-8.
41. Ulm K,. A simple method to calculate the confidence interval of a standardized mortality ratio. Am J Epidemiol 1990; 131: 373-5.